Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus

Cellular and Molecular Immunology

Volumn 13, Issue 2, 2016, Pages 180-190

  Zhang, Naru ^a   Channappanavar, Rudragouda ^b   Ma, Cuiqing ^a   Wang, Lili ^a   Tang, Jian ^a,c,f   Garron, Tania ^d   Tao, Xinrong ^d   Tasneem, Sumaiya ^a   Lu, Lu ^e   Tseng, Chien Te K ^d   Zhou, Yusen ^c,f   Perlman, Stanley ^b   Jiang, Shibo ^a,e   Du, Lanying ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d University of Texas Medical Branch School of Medicine   (United States)

^e FUDAN UNIVERSITY   (China)

^f Central South University   (China)

Author keywords

adjuvant effects; MERS; MERS CoV; receptor binding domain; subunit vaccine

Indexed keywords

ALUMINUM HYDROXIDE; CORONAVIRUS SPIKE GLYCOPROTEIN; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS VACCINE; MIFAMURTIDE; MONTANIDE ISA 51; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; S377-588 FC PROTEIN; UNCLASSIFIED DRUG; VIRUS VACCINE; IMMUNOGLOBULIN G; SUBUNIT VACCINE; VIRUS ANTIBODY;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORONAVIRUS INFECTION; FEMALE; IMMUNOGENICITY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; MOUSE; NONHUMAN; PROTEIN DOMAIN; RECEPTOR BINDING DOMAIN; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CORONAVIRUS INFECTIONS; HUMAN; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINES, SUBUNIT; VIRAL VACCINES;

EID: 84959905145     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.03     Document Type: Article

References (72)

1. Zaki AM, van BS, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367: 1814-1820.
2. Yang Y, Du L, Liu C, Wang L, Ma C, Tang J et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci USA 2014; 111: 12516-12521.
3. Ithete NL, Stoffberg S, Corman VM, Cottontail VM, Richards LR, Schoeman MC et al. Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. Emerg Infect Dis 2013; 19: 1697-1699.
4. Memish ZA, Mishra N, Olival KJ, Fagbo SF, Kapoor V, Epstein JH et al. Middle East respiratory syndrome coronavirus in bats, saudi arabia. Emerg Infect Dis 2013; 19.
5. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM et al. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 2014; 370: 2499-2505.
6. Briese T, Mishra N, Jain K, Zalmout IS, Jabado OJ, Karesh WB et al. Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through wholegenome analysis and virus cultured from dromedary camels in Saudi Arabia. MBio 2014; 5: e01146-14.
7. Azhar EI, Hashem AM, El-Kafrawy SA, Sohrab SS, Aburizaiza AS, Farraj SA et al. Detection of the middle East respiratory syndrome coronavirus genome in an air sample originating from a camel barn owned by an infected patient. MBio 2014; 5: e01450-14.
8. Mailles A, Blanckaert K, Chaud P, van der Werf S, Lina B, Caro V et al. First cases of Middle East Respiratory Syndrome Coronavirus (MERSCoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveill 2013; 18: 20502.
9. Lu L, Liu Q, Du L, Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect 2013; 15: 625-629.
10. Hotez PJ, Bottazzi ME, Tseng CT, Zhan B, Lustigman S, Du L et al. Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect 2014; 16: 529-531.
11. Li F. Evidence for a common evolutionary origin of coronavirus spike protein receptor-binding subunits. J Virol 2012; 86: 2856-2858.
12. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495: 251-254.
13. Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013; 500: 227-231.
14. Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013; 23: 986-993.
15. Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G et al. A truncated receptorbinding domain of MERS-CoV spike protein potently inhibits MERSCoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 2013; 8: e81587.
16. Mou H, Raj VS, van Kuppeveld FJ, Rottier PJ, Haagmans BL, Bosch BJ. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013; 87: 9379-9383.
17. Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CT et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptorbinding fragments-the importance of immunofocusing in subunit vaccine design. Vaccine 2014; 32: 6170-6176.
18. Deng MP, Hu ZH, Wang HL, Deng F. Developments of subunit and VLP vaccines against influenza A virus. Virol Sin 2012; 27: 145-153.
19. Du L, He Y, Jiang S, Zheng BJ. Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today (Barc) 2008; 44: 63-73.
20. Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines 2014; 13: 761-774.
21. Chen DJ, Osterrieder N, Metzger SM, Buckles E, Doody AM, DeLisa MP et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci USA 2010; 107: 3099-3104.
22. Foged C. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther Deliv 2011; 2: 1057-1077.
23. Sivakumar SM, Safhi MM, Kannadasan M, Sukumaran N. Vaccine adjuvants-current status and prospects on controlled release adjuvancity. Saudi Pharm J 2011; 19: 197-206.
24. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82: 488-496.
25. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183: 6186-6197.
26. Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine 2013; 31: 5745-5753.
27. Launay O, Duval X, Fitoussi S, Jilg W, Kerdpanich A, Montellano M et al. Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials. BMC Infect Dis 2013; 13: 435.
28. Patil HP, Murugappan S, ter VW, Meijerhof T, de HA, Frijlink HW et al. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. J Control Release 2014; 174: 51-62.
29. Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY et al. Safety and immunogenicity of multimeric-001-a novel universal influenza vaccine. J Clin Immunol 2012; 32: 595-603.
30. Du L, Zhao G, Sun S, Zhang X, Zhou X, Guo Y et al. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PLoS One 2013; 8: e53568.
31. Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly. Clin Vaccine Immunol 2014; 21: 989-996.
32. Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001; 17: 135-140.
33. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 2008; 26: 3209-3222.
34. Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT et al. Intranasal vaccination with recombinant receptor-binding domain of MERSCoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 2014; 32: 2100-2108.
35. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014; 111: 4970-4975.
36. Tao X, Hill TE, Morimoto C, Peters CJ, Ksiazek TG, Tseng CT. Bilateral entry and release of Middle East respiratory syndrome coronavirus induces profound apoptosis of human bronchial epithelial cells. J Virol 2013; 87: 9953-9958.
37. Du L, Zhao G, Yang Y, Qiu H, Wang L, Kou Z et al. A conformation dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol 2014; 88: 7045-7053.
38. Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 2011; 203: 1165-1173.
39. Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated splitvirus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin Vaccine Immunol 2011; 18: 1358-1364.
40. Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del GG et al. Antibody response against heterogeneous circulating influenza virus strains elicited by. Vaccine 2010; 28: 4123-4129.
41. Martyn JC, Cardin AJ, Wines BD, Cendron A, Li S, Mackenzie J et al. Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptors. Arch Virol 2009; 154: 1129-1138.
42. Chen H, Xu X, Jones IM. Immunogenicity of the outer domain of a HIV-1 clade C gp120. Retrovirology 2007; 4: 33.
43. Li Y, Du L, Qiu H, Zhao G, Wang L, Zhou Y et al. A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses. Biosci Trends 2013; 7: 129-137.
44. Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 2007; 25: 2832-2838.
45. Du L, Leung VH, Zhang X, Zhou J, Chen M, He W et al. A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PLoS One 2011; 6: e16555.
46. Wang J, Tricoche N, Du L, Hunter M, Zhan B, Goud G et al. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLoS One 2012; 7: e37019.
47. De Groot AS, Moise L, McMurry JA, Wambre E, Van OL, Moingeon P et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 2008; 112: 3303-3311.
48. Mastelic B, Ahmed S, Egan WM, Del GG, Golding H, Gust I et al. Mode of action of adjuvants: implications for vaccine safety and design. Biologicals 2010; 38: 594-601.
49. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009; 9: 287-293.
50. Exley C, Siesjo P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol 2010; 31: 103-109.
51. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008; 65: 3231-3240.
52. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316: 1628-1632.
53. O'Hagan DT, Ott GS, De GE, Seubert A. The mechanism of action of MF59-an innately attractive adjuvant formulation. Vaccine 2012; 30: 4341-4348.
54. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 2008; 105: 10501-10506.
55. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009; 106: 7962-7967.
56. + T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009; 106: 3877-3882.
57. Hofmeister Y, Planitzer CB, Farcet MR, Teschner W, Butterweck HA, Weber A et al. Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus. J Virol 2011; 85: 1896-1899.
58. Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, Chan KH et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 2003; 362: 1353-1358.
59. Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S et al. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARSCoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol 2008; 180: 948-956.
60. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 2004; 324: 773-781.
61. He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol 2006; 176: 6085-6092.
62. Du L, Zhao G, Chan CC, Sun S, Chen M, Liu Z et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 2009; 393: 144-150.
63. Leenaars M, Koedam MA, Hendriksen CF, Claassen E. Immune responses and side effects of five different oil-based adjuvants in mice. Vet Immunol Immunopathol 1998; 61: 291-304.
64. Pineton de CG, Body-Malapel M, Frey-Wagner I, Djouina M, Deknuydt F, Atrott K et al. Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. Mucosal Immunol 2014; 7: 589-601.
65. Todoroff J, Lemaire MM, Fillee C, Jurion F, Renauld JC, Huygen K et al. Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice. PLoS One 2013; 8: e63344.
66. Podda A, Del GG. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003; 2: 197-203.
67. Fox CB, Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 2013; 12: 747-758.
68. Sindoni D, La F, V, Squeri R, Cannavo G, Bacilieri S, Panatto D et al. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity. J Prev Med Hyg 2009; 50: 121-126.
69. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010; 10: 639-651.
70. Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin Vaccine Immunol 2010; 17: 1817-1819.
71. Mbow ML, De GE, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010; 22: 411-416.
72. Tregoning JS, Buffa V, Oszmiana A, Klein K, Walters AA, Shattock RJ. A "prime-pull" vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice. PLoS One 2013; 8: e80559.